To establish a standard and reproducible protocol for pancreatic tumor organoid platform, we started from pancreatic tumors developed by orthotopic injection of OVA257‐264 antigen‐presented KPC (LSL‐Kras+/G12D; LSL‐Trp53+/R172H; PDX1‐Cre) cells into the parenchyma of C57BL/6 mice. Here, KRAS is linked to pancreatic neoplasm.